Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,170 shares of the company’s stock after purchasing an additional 10,319 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Roivant Sciences were worth $575,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in Roivant Sciences during the 4th quarter valued at approximately $33,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Roivant Sciences in the 3rd quarter worth approximately $44,000. Covestor Ltd grew its position in shares of Roivant Sciences by 165,040.0% in the 3rd quarter. Covestor Ltd now owns 8,257 shares of the company’s stock worth $96,000 after acquiring an additional 8,252 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Roivant Sciences by 16.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 15,782 shares of the company’s stock worth $184,000 after acquiring an additional 2,258 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Roivant Sciences by 99.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,797 shares of the company’s stock worth $231,000 after acquiring an additional 9,856 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Down 0.2 %

ROIV opened at $10.88 on Friday. Roivant Sciences Ltd. has a one year low of $8.06 and a one year high of $13.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. The stock’s fifty day moving average is $10.93 and its 200-day moving average is $10.36. The company has a market capitalization of $8.77 billion, a PE ratio of 2.09 and a beta of 1.34.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The company had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. On average, equities analysts predict that Roivant Sciences Ltd. will post -1.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ROIV. Piper Sandler initiated coverage on Roivant Sciences in a research report on Friday, January 5th. They issued an “overweight” rating and a $20.00 target price for the company. TheStreet raised Roivant Sciences from a “d” rating to a “c+” rating in a report on Tuesday, February 13th. Truist Financial reissued a “buy” rating and issued a $23.00 price target on shares of Roivant Sciences in a report on Monday, March 25th. Deutsche Bank Aktiengesellschaft raised their price target on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Wolfe Research initiated coverage on Roivant Sciences in a report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.90.

Insider Buying and Selling

In related news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the transaction, the chief operating officer now directly owns 532,207 shares in the company, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.60% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.